Lexicon Pharmaceuticals Inc Stock Price, News & Analysis

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q2 2025 financial results, highlighting significant progress across its pipeline. The company posted net income of $3.3 million ($0.01 per share) compared to a loss of $53.4 million in Q2 2024, with revenues increasing to $28.9 million from $1.6 million year-over-year.

Key developments include ongoing partnership discussions for pilavapadin following Phase 2b results, progress in IND-enabling studies for LX9851 under a $1 billion potential deal with Novo Nordisk, and advancement of the SONATA Phase 3 study for sotagliflozin in HCM. The company ended Q2 with $139 million in cash and investments plus $29 million in restricted cash.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or higher for ten consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2). This development ensures LXRX's continued listing on the Nasdaq exchange.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET (7:30 a.m. CT) on the same day.

Management will present the financial results and provide a business update during the call. Investors can access the live webcast through the Events page on Lexicon's investor relations website, and those wishing to ask questions can register to receive dial-in information.

Lexicon Pharmaceuticals (Nasdaq: LXRX) will present patient-reported data on diabetic peripheral neuropathic pain (DPNP) at the ASPN 2025 conference in Miami Beach, Florida. The presentation focuses on patient experiences with DPNP, a debilitating chronic complication affecting approximately 9 million patients in the U.S.

The research highlights that DPNP impacts 30% of type 1 diabetes patients and 50% of type 2 diabetes patients, causing symptoms like burning pain and numbness in extremities. The study aims to inform the development of pilavapadin, Lexicon's investigational non-opioid treatment for DPNP, and raise awareness among healthcare professionals about patient burden.

Lexicon Pharmaceuticals (LXRX) presented post-hoc analysis data at the ADA's 85th Scientific Sessions showing that sotagliflozin, when added to insulin therapy, reduces hypoglycemic events in Type 1 diabetes patients. The analysis, based on inTandem 1 and 2 Phase 3 trials data, demonstrated that sotagliflozin treatment resulted in lower hypoglycemia rates compared to placebo, particularly in patients with blood glucose ≤55 mg/dL. The effect was consistent across different kidney function groups. This finding is significant as hypoglycemia accounts for 5% of T1D hospitalizations and up to 10% of T1D deaths, with chronic kidney disease affecting 20-40% of T1D patients being a major risk factor.

Lexicon Pharmaceuticals (LXRX) will present clinical data at the 85th ADA Scientific Sessions on June 20-23, 2025, in Chicago. The presentation focuses on sotagliflozin's ability to reduce hypoglycemic events in type 1 diabetes patients across different kidney function levels, categorized by eGFR ranges. Dr. M. Belinda Hardin will deliver an oral presentation on June 22 discussing these findings. Additionally, Lexicon will present topline results from their PROGRESS Phase 2b study of pilavapadin (LX9211), evaluating its effectiveness in treating diabetic peripheral neuropathic pain. The presentations align with ADA's 2025 Standards of Care emphasis on preventing hypoglycemia in type 1 diabetes management.

Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its upcoming participation in the 2025 Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5 at 12:50 p.m. ET in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Lexicon Pharmaceuticals (NASDAQ: LXRX) presented the design of its SONATA-HCM Phase 3 clinical trial at Heart Failure 2025, evaluating sotagliflozin for both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). The study is actively enrolling 500 patients across 20 countries, with all sites expected to be operational by September 2025.

The trial aims to assess sotagliflozin's efficacy on symptoms, function, and patient-reported outcomes in HCM patients. The primary endpoint measures symptom improvement using the Kansas City Cardiomyopathy Questionnaire at week 26. Recent evidence published in The Lancet (February 2025) suggests sotagliflozin's dual SGLT1 and SGLT2 inhibition reduces major adverse cardiovascular events.

If successful, the study could support a supplemental new drug application (sNDA) for sotagliflozin in both HCM types, addressing a significant unmet need, particularly for non-obstructive HCM where no approved therapies exist.

Lexicon Pharmaceuticals (LXRX) reported Q1 2025 financial results and business updates. The company secured an exclusive license agreement with Novo Nordisk for LX9851, potentially worth up to $1 billion in payments. Their Phase 2b PROGRESS study confirmed 10 mg pilavapadin as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain. Q1 financial results showed revenues of $1.3 million, R&D expenses of $15.3 million, and reduced SG&A expenses to $11.6 million. Net loss improved to $25.3 million ($0.07 per share) from $48.4 million in Q1 2024. The company ended Q1 with $194.8 million in cash and investments. Lexicon is advancing multiple pipeline programs, including sotagliflozin for hypertrophic cardiomyopathy in the SONATA-HCM Phase 3 study.